NCT03913949View on ClinicalTrials.gov

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

October 20, 2024

Study Completion Date

December 31, 2025

Conditions
Chronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Interventions
DRUG

APG-2575

Multiple dose cohorts, PO, every day (QD) of a 28-day cycle

Trial Locations (5)

300020

Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

Unknown

Anhui Procincial hospital, Hefei

Henan Provincial Oncology Hospital, Zhengzhou

Zhongnan Hospital of Wuhan University, Wuhan

The First Affiliated Hospital, Zhejiang University School of Medicin, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Suzhou Yasheng Pharmaceutical Co., Ltd.

INDUSTRY

lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT03913949 - A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter